2
项与 P3C541b Lipopeptide(National Institute of Allergy & Infectious Diseases) 相关的临床试验A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Immunotherapeutic P3C541b in HIV-1 Seropositive Human Subjects
To evaluate an HIV lipopeptide immunotherapeutic, P3C541b, at two dose levels administered subcutaneously in HIV-seropositive patients.
A Phase I Safety and Immunogenicity Trial of UBI HIV Lipopeptide Vaccine Component P3C541b in HIV-1 Seronegative Human Subjects
To evaluate an HIV synthetic lipopeptide candidate vaccine component, P3C541b, at two dose levels, administered subcutaneously (s.c.) in a randomized, double-blind, placebo controlled study.
100 项与 P3C541b Lipopeptide(National Institute of Allergy & Infectious Diseases) 相关的临床结果
100 项与 P3C541b Lipopeptide(National Institute of Allergy & Infectious Diseases) 相关的转化医学
100 项与 P3C541b Lipopeptide(National Institute of Allergy & Infectious Diseases) 相关的专利(医药)
100 项与 P3C541b Lipopeptide(National Institute of Allergy & Infectious Diseases) 相关的药物交易